Tocagen — Forte Biosciences — Investor Presentation (August 2024)
46 slides from Tocagen's investor presentation, Aug 14, 2024
Slide 1: Forte Biosciences Corporate Deck
Exhibit 99.2 FORTE BIOSCIENCES CORPORATE DECK AUGUST 14,2024
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities
Slide 3: Experienced Management
EXPERIENCED MANAGEMENT Forte’s management has extensive experience in manufacturing, quality, regulatory and clinical development Paul Wagner, Ph.D., CFA – CEO Tony Riley – Chief Financial Officer Chris Roenfeldt, PMP – Chief Operating Officer Steven Ruhl – Chief Technical Officer Barbara Finck, MD
Slide 4: Strong Board of Directors
Forte Biosciences, Inc is a clinical-stage public biotechnology company (Nasdaq: FBRX) Strong Board of Directors comprised of leaders in industry including: Scott Brun, MD – Former head of Abbvie product development Steve Doberstein, PhD – Former Chief Scientific Officer of Nektar Lawrence Eichenfie
Slide 5: FB102 Program Overview
FB102 PROGRAM OVERVIEW
Slide 6: Clinical Stage FB102 Overview
CLINICAL STAGE FB102 OVERVIEW • CD122 is a subunit of the intermediate affinity IL-2/IL-15 receptor expressed on NK cells,certainT cell subtypes an is a subunit of the high affinity IL-2 receptor expressed on Tregs. • FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the I
Slide 7: Advancing Clinical Stage FB102
ADVANCING CLINICAL STAGE FB102 • Phase 1 healthy volunteer SAD/MAD successfully completed and demonstrated a good safety profile. • Forte is initiating celiac disease patient study in 3Q24 and data is expected by 2Q25. • Significant amount of proof-of-concept preclinical data across numerous indicat
Slide 8: Highlights of Existing Preclinical Anti-CD122 Proof-of-Concept Data
HIGHLIGHTS OF EXISTING PRECLINICALANTI-CD122 PROOF-OF-CONCEPT DATA
Slide 9: Partial List of Positive POC Animal Data for Anti-CD122
PARTIALLIST OF POSITIVE POCANIMAL DATAFORANTI-CD122 HIGHLIGHTS FB102“PIPELINE-IN-A-PRODUCT” POTENTIAL Disease Species Outcome Reference Alopecia areata Mouse Prevented fur loss Nature Med,2014 Improved IL-15-induced mucosal Celiac disease Mouse PNAS,2009 damage GVHD Mouse Prolonged survival JN Bio p
Slide 10: FB102 in Proof-of-Concept Autoimmune Preclinical Data
FB102 IN PROOF-OF-CONCEPT AUTOIMMUNE PRECLINICAL DATA
Slide 11: Preclinical Efficacy Data in Humanized Mouse Model of Acute GVHD
GENERATING PRECLINICAL EFFICACY DATAINA HUMANIZED MOUSE MODEL OFACUTE GVHD Humanized mouse model of graft vs host disease Aggressive,rapid-onset of GvHD (100% mortality within 30 days) due to both T and NK cell engraftment NCG (immunodeficient) Transplant with human with human IL-15 expression PBMC
Slide 12: Dose-Ranging Investigation of FB102 in Humanized Mouse Model of Acute GVHD
DOSE-RANGING INVESTIGATION OF FB102 INA HUMANIZED MOUSE MODEL OFACUTE GVHD:THERAPEUTIC MODE Irradiation& End of PBMC transplantation treatment Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 FB102 Once-daily IP administration Start dosing on Day 5, (75,125,175 mpk) once daily Vehicle Once-daily IP administrati
Slide 13: FB102 Survival Benefits: Therapeutic Model
FB102 SURVIVAL BENEFITS:THERAPEUTIC MODEL Start of daily treatment FB102 100% superior to FB102(75): 90% aGvHD FB102(175):90% 80% FB102(125):80% standard of care, 60% Ruxolitinib: 60% ruxolitinib, 40% head-to-head 20% 0% Vehicle: 0% 1 3 5 7 9 11 13 15 Study day P=0.0001 for FB102 (75,175) vsVehicle
Slide 14: Mono vs Combination Therapies with FB102, Ruxolitinib or Corticosteroids
MONOVS COMBINATION THERAPIESWITH FB102,RUXOLITINIB OR CORTICOSTEROIDS Irradiation& End of study PBMC injection (D18) Day 1 5 8 12 15 18 Ruxolitinib Twice-daily oral (60 mpk) FB102+Ruxolitinib Once-daily IP + twice-daily oral (75 mpk+60 mpk) Placebo Once-daily IP + twice-daily oral (Combination of ve
Slide 15: FB102 Survival Benefits: Combination with Ruxolitinib
FB102 SURVIVAL BENEFITS:COMBINATION OF FB102WITH RUXOLITINIB SIGNIFICANTLY SUPERIORTO RUXOLITINIBALONE Start of daily treatment FB102 + Rux 100% combo FB102+Rux: 90% significantly 80% superior to 60% standard of care single agent, 40% ruxolitinib, Ruxolitinib: 30% head-to-head 20% Vehicle:0% 0% 1 3
Slide 16: Phase 1 Healthy Volunteer Study
PHASE 1 HEALTHYVOLUNTEER STUDY
Slide 17: FB102 Phase 1 Healthy Volunteer Summary
FB102 PHASE 1 HEALTHYVOLUNTEER SUMMARY • Phase 1 healthy volunteer SAD/MAD successfully completed and demonstrated a good safety profile. • Significant reductions in NK cell pharmacodynamic marker of FB102 mechanism were observed supporting the in-vitro as well as the NHP data and the mechanism of a
Slide 18: FB102 Indication Review
FB102 INDICATION REVIEW
Slide 19: Partial List of Positive POC Animal Data for Anti-CD122
PARTIALLIST OF POSITIVE POCANIMAL DATAFORANTI-CD122 HIGHLIGHTS FB102“PIPELINE-IN-A-PRODUCT” POTENTIAL Disease Species Outcome Reference Alopecia areata Mouse Prevented fur loss Nature Med,2014 Improved IL-15-induced mucosal Celiac disease Mouse PNAS,2009 damage GVHD Mouse Prolonged survival JN Bio p
Slide 20: Celiac Disease
CELIAC DISEASE
Slide 21: No Approved Therapies for Celiac Disease; Multi-Billion-Dollar Opportunity
NOAPPROVEDTHERAPIES FOR CELIAC DISEASE; POTENTIAL FORA MULTI-BILLION-DOLLAR OPPORTUNITY ï,¡ Celiac disease ï,¡ Celiac disease is an autoimmune disease that’s triggered by consuming gluten and results in damage to the small intestineï,¡ Symptom include diarrhea, fatigue, headaches, anemia, nausea,der
Slide 22: IL-2 and IL-15 in Celiac Disease
IL-2AND IL-15 IN CELIAC DISEASE (CED) IL-2 ï,¡ Clear genetic basis for involvement of IL-2 in CeD ï,¡ Gluten-induced IL-2 production differentiates true CeD from non-gluten induced GI symptomsï,¡ IL-2 strongly correlates with symptom severity and serum IL-2 peaks within 4 hours after gluten exposure
Slide 23: FB102: Prevention of Gluten-Induced Intestinal Damage in Celiacs
FB102:PREVENTION OF GLUTEN-INDUCED INTESTINAL DAMAGE IN CELIACS BY BLOCKING IL-15AND IL-2ACTIVATION OF CD8+ T CELLS healthy epithelium damaged epithelium CD8+ CD8+ cells Tcell damage IL-15 epithelium FB102 blocks IL-15 and IL-2 IL-2 APC with Gluten gluten specific peptide CD4+ Tcell 23 Levescot 2022
Slide 24: Anti-CD122 Antibody Reverses IL-15 Induced Intestinal Damage in Mice
ANTI-CD122ANTIBODY REVERSES IL-15 INDUCED INTESTINAL DAMAGE IN MICE ï,¡ Transgenic mice overexpressing IL-15 in the intestine have extensive inflammation and damage to the duodeno-jejunal region with extensive blunting of villi ï,¡ Extensive influx of NKG2D-expressing CD8+T cells, and enterocytes ex
Slide 25: Vitiligo
VITILIGO
Slide 26: Large Unmet Need in Vitiligo Presents a Multi-Billion Dollar Opportunity
LARGE UNMET NEED INVITILIGO PRESENTSA MULTI-BILLION DOLLAR OPPORTUNITY ï,¡ Vitiligo ï,¡ Vitiligo is an autoimmune disease of the skin driven by pathogenicT cells that kill melanocytes and create white spots. ï,¡ Vitiligo results in sensitive skin (increasing likelihood of sub burns),eye abnormalitie
Slide 27: IL-15 Activation of Pathogenic CD8+ T Cells in Skin
IL-15ACTIVATION OF PATHOGENIC CD8+T CELLS IN SKIN Vitiligo patients have unpigmented skin due to activated FB102 blocks activation of pathogenicT cells,restoring pathogenicT cells killing melanocytes melanocyte health and skin pigmentation Tokura Front Immunol.2021 PMID 33633737 27
Slide 28: IL-2 Therapy Drives Vitiligo
IL-2THERAPY DRIVES VITILIGO EnhancedSurvivalAssociatedwithVitiligoExpressionduring MaintenanceBiotherapyforMetastaticMelanoma(1) Peter D. Boasberg1, Dave S.B. Hoon2, Lawrence D. Piro1, Maureen A. Martin1, Akhide Fujimoto2,Timothy S. Kristedja1, Sandeep Bhachu1, Xing Ye2, Regina R. Deck1 and Steven J
Slide 29: Anti-CD122 Antibody Effective in Mouse Vitiligo Model
ANANTI-CD122ANTIBODY IS EFFECTIVE INA MOUSE VITILIGO MODELWITH ESTABLISHED DISEASE Repigmentation study Melanin-reactive T cells Melanin-reactive T cells eliminated pigment in tail eliminated pigment in tail Vehicle(control) treatment Anti-CD122 treatment did not restore pigment restored pigmentatio
Slide 30: Anti-CD122 in Mouse Vitiligo Model: Durable Response with Infrequent Dosing
ANTI-CD122 INA MOUSE MODEL OFVITILIGO:POTENTIAL OF DURABLE RESPONSEWITH INFREQUENT DOSING REGIMEN Note:anti-mouse CD122 (surrogate molecule) was used in these studies. 30
Slide 31: Type 1 Diabetes
TYPE 1 DIABETES
Slide 32: Type 1 Diabetes Caused by Autoreactive T Cells Destroying Beta Cells
TYPE 1 DIABETES IS CAUSED BYAUTOREACTIVET CELLS DESTROYING INSULIN-PRODUCING PANCREATIC BETA CELLS ï,¡ Type 1 diabetes (T1D) is classified by three stages of progression ï,¡ Stage 1:at least one diabetes-related autoantibody but has normal blood sugar and no symptoms ï,¡ Stage 2:at least two diabete
Slide 33: FB102 Predicted to Block IL-15 Activation of Beta-Cell Specific CD8+ T Cells
FB102 IS PREDICTEDTO BLOCK IL-15 FROMACTIVATING BETA-CELL SPECIFIC CD8+T CELLS,PREVENTING BETA-CELL KILLING IL-15/ FB102 blocks IL15RA IL-15 binding CD122/ CD132 CD8+T cells with receptors recognizing Environmental stress causes β-cells to β-cell specific peptides are enriched in upregulate MHC an
Slide 34: Single Injection of Anti-CD122 Delays Diabetes Onset in NOD Mice
A SINGLE INJECTION OFANTI-CD122ANTIBODY DELAYS DIABETES ONSET IN NOD MICEANDALSO KNOCKS DOWN NK CELLS Yuan 2018 JCI Insight PMID 29367461 34
Slide 35: Graft versus Host Disease (GVHD)
GRAFTVERSUS HOST DISEASE (GVHD)
Slide 36: GVHD: A Serious Complication of Allogeneic Stem Cell Transplantation
GRAFTVS HOST DISEASE (GVHD):A SERIOUS COMPLICATION OF ALLOGENEIC STEM CELLTRANSPLANTATION ï,¡ Acute Graft vs Host Disease Cause:donor immune cells attack host tissues ï,¡ Occurs in up to 50% of recipients. ï,¡ 2 year mortality >70% mortality in Stage 3 and 4 disease ï,¡ Usually combination or organs
Slide 37: CD8 and NK Cells in Pathogenesis of Acute GVHD
CD8AND NK CELLS INTHE PATHOGENESIS OFACUTE GVHD: POTENTIAL OFANTI-CD122ANTAGONISMWITH FB102 Anti-CD122:blocking key cellular mediators of GVHD IFNg IL-2 Inflammation & apoptosis Devetten MP, Biol Blood Marrow Transplant. 2004;10:815. Simonetta F, Front Immunol. 2017;8:465. Khandelwal P, Biol Blood M
Slide 38: Acute GVHD: Treatment Paradigm and Development Pipeline
ACUTE GVHD:TREATMENT PARADIGMAND DEVELOPMENT PIPELINE https://www.lls.org/booklet/graft-versus-host-disease https://www.jakafi.com/pdf/prescribing-information.pdf 38
Slide 39: Dose-Ranging Investigation of FB102 in Humanized Mouse Model of Acute GVHD
DOSE-RANGING INVESTIGATION OF FB102 INA HUMANIZED MOUSE MODEL OFACUTE GVHD:THERAPEUTIC MODE Irradiation& End of PBMC transplantation treatment Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 FB102 Once-daily IP administration Start dosing on Day 5, (75,125,175 mpk) once daily Vehicle Once-daily IP administrati
Slide 40: FB102 Survival Benefits: Therapeutic Model
FB102 SURVIVAL BENEFITS:THERAPEUTIC MODEL Start of daily treatment FB102 100% superior to FB102(75): 90% aGvHD FB102(175):90% 80% FB102(125):80% standard of care, 60% Ruxolitinib: 60% ruxolitinib, 40% head to head 20% 0% Vehicle: 0% 1 3 5 7 9 11 13 15 Study day P=0.0001 for FB102 (75,175) vsVehicle
Slide 41: Mono vs Combination Therapies with FB102, Ruxolitinib or Corticosteroids
MONOVS COMBINATION THERAPIESWITH FB102,RUXOLITINIB OR CORTICOSTEROIDS Irradiation& End of study PBMC injection (D18) Day 1 5 8 12 15 18 Ruxolitinib Twice-daily oral (60 mpk) FB102+Ruxolitinib Once-daily IP + twice-daily oral (75 mpk+60 mpk) Placebo Once-daily IP + twice-daily oral (Combination of ve
Slide 42: FB102 Survival Benefits: Combination with Ruxolitinib
FB102 SURVIVAL BENEFITS:COMBINATION OF FB102WITH RUXOLITINIB SIGNIFICANTLY SUPERIORTO RUXOLITINIBALONE Start of daily treatment FB102 + Rux 100% combo FB102+Rux: 90% significantly 80% superior to 60% standard of care single agent, 40% ruxolitinib, Ruxolitinib: 30% head-to-head 20% Vehicle:0% 0% 1 3
Slide 43: Translation of Humanized Acute GVHD Mouse Findings into Patient Response
TRANSLATION OF HUMANIZEDACUTE GVHD MOUSE FINDINGS INTO PATIENT RESPONSE:PROMISING FB102 RESULTS Magnitude of FB102 preclinical efficacy correlates with positive clinical response. Preclinical Data Indication/ Clinical Data Company Candidate Mechanism (survival in humanized Phase (Day 28 ORR) GVHD mo
Slide 44: Summary
SUMMARY
Slide 45: Clinical Stage FB102 Overview
CLINICAL STAGE FB102 OVERVIEW • CD122 is a subunit of the intermediate affinity IL-2/IL-15 receptor expressed on NK cells,certainT cell subtypes an is a subunit of the high affinity IL-2 receptor expressed on Tregs. • FB102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the I
Slide 46: FB102 Program Summary
FB102 PROGRAM SUMMARY • Phase 1 healthy volunteer SAD/MAD successfully completed and demonstrated a good safety profile. • Significant reductions in NK cell pharmacodynamic marker of FB102 mechanism observed supporting the in vitro as well as the NHP data and mechanism of action of FB102. • Forte is
Forte Biosciences — Investor Presentation (August 2024) on 6ix